潜质未定克隆性造血致动脉粥样硬化及NLRP3炎性小体治疗作用研究进展

doi:10.20047/j.issn1673-7210.2023.21.08

摘要
图/表
参考文献(34)
相关文章 (15)

全文: PDF (563 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要近年来有研究显示，体细胞驱动基因突变导致的潜质未定克隆性造血（CHIP）刺激炎症标志物升高是动脉粥样硬化性心血管疾病发生及发展的因素之一，核苷酸结合寡聚结构域样受体家族Pyrin结构域中的NLRP3炎性小体，是细胞焦亡的重要调控分子，在其炎症过程中起着关键作用。MCC950作为一种特定的小分子抑制剂，对于NLRP3炎性小体介导细胞焦亡具有选择性的抑制作用，因此，MCC950有望成为临床治疗CHIP介导炎症所致动脉粥样硬化性心血管疾病的有效药物。本文从CHIP相关基因突变入手，概述了NLRP3炎性小体调控细胞焦亡作用于动脉粥样硬化发病机制，以及NLRP3炎性小体选择性抑制剂MCC950作用于CHIP诱发动脉粥样硬化的作用及机制，为临床治疗动脉粥样硬化开辟新的道路。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	陈雅芳1　　李思1　　史洋2　　魏丽萍3

关键词 ：潜质未定克隆性造血, NLRP3炎性小体, 动脉粥样硬化, 细胞焦亡, MCC950, 突变

Abstract：In recent years, some studies have shown that the increase of inflammatory markers, which results from the clonal hematopoiesis of indeterminate potential (CHIP) caused by somatic cell driven gene mutation, is one of the factors for the occurrence and development of atherosclerotic cardiovascular disease. The NLRP3 inflammasome in the Pyrin domain of the nucleotide-binding oligomeric domain-like receptor family, is an important regulator of pyroptosis and plays a key role in the inflammatory process. As a specific small-molecule inhibitor, MCC950 has a selective inhibitory effect on NLRP3 inflammasome mediated pyroptosis. Therefore, MCC950 is expected to become an effective drug for the clinical treatment of atherosclerotic cardiovascular diseases caused by inflammation mediated by CHIP. Starting from the related mutation of CHIP induced gene, this paper summarizes the pathogenesis of atherosclerosis mediated by the regulation of pyroptosis by NLRP3 inflammasome, and the role and mechanism of selective inhibitor MCC950 of NLRP3 inflammasome on the induction of atherosclerosis by CHIP, so as to provide a basis for clinical treatment of atherosclerosis.

Key words： Clonal hematopoiesis of indeterminate potential NLRP3 inflammasome Atherosclerosis Pyroptosis MCC950 Mutation

基金资助:国家自然科学基金面上项目（52173285）；
京津冀专项项目（19JCZDJC63900）。

通讯作者: 魏丽萍（1972.7-），女，博士，主任医师，主要从事冠心病临床与基础研究、化疗药物心肌损伤及保护研究。

作者简介: 陈雅芳（1998.12-），女，天津中医药大学研究生院2021级中西医结合临床专业在读硕士研究生，主要从事心血管方面的研究。

引用本文:

陈雅芳1　　李思1　　史洋2　　魏丽萍3. 潜质未定克隆性造血致动脉粥样硬化及NLRP3炎性小体治疗作用研究进展[J]. 中国医药导报, 2023, 20(21): 40-44.
CHEN Yafang1 LI Si1 SHI Yang2 WEI Liping3. Research progress on atherosclerosis induced by clonal hematopoiesis of indeterminate potential and the therapeutic effect of NLRP3 inflammasome. 中国医药导报, 2023, 20(21): 40-44.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.21.08 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I21/40

[1] Libby P. The changing landscape of atherosclerosis [J]. Nature，2021，592（7855）：524-533.
[2] Steensma DP，Bejar R，Jaiswal S，et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes [J]. Blood，2015，126（1）：9-16.
[3] Jaiswal S，Libby P. Clonal haematopoiesis：connecting ageing and inflammation in cardiovascular disease [J]. Nat Rev Cardiol，2020，17（3）：137-144.
[4] Marnell CS，Bick A，Natarajan P. Clonal hematopoiesis of indeterminate potential （CHIP）：linking somatic mutations，hematopoiesis，chronic inflammation and cardiovascular disease [J]. J Mol Cell Cardiol，2021，161：98-105.
[5] Bhattacharya R，Zekavat SM，Haessler J，et al. Clonal hemat- opoiesis is associated with higher risk of stroke [J]. Stroke，2022，53（3）：788-797.
[6] Sano S，Oshima K，Wang Y，et al. Tet2-mediated clonal hem- atopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome [J]. J Am Coll Cardiol，2018，71（8）：875-886.
[7] Murphy AJ，Dragoljevic D，Natarajan P，et al. Hematopoiesis of indeterminate potential and atherothrombotic risk [J]. Thromb Haemost，2022，122（9）：1435-1442.
[8] Jaiswal S，Natarajan P，Silver AJ，et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease [J]. N Engl J Med，2017，377（2）：111-121.
[9] Garcia-Outeiral V，de la Parte C，Fidalgo M，et al. The complexity of TET2 functions in pluripotency and development [J]. Front Cell Dev Biol，2020，8：630754.
[10] Fuster JJ，MacLauchlan S，Zuriaga MA，et al. Clonal hema- topoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice [J]. Science，2017，355（6327）：842-847.
[11] Venugopal K，Feng Y，Shabashvili D，et al. Alterations to DNMT3A in hematologic malignancies [J]. Cancer Res，2021， 81（2）：254-263.
[12] Cobo I，Tanaka T，Glass CK，et al. Clonal hematopoiesis driven by DNMT3A and TET2 mutations：role in monocyte and macrophage biology and atherosclerotic cardiovascular disease [J]. Curr Opin Hematol，2022，29（1）：1-7.
[13] Wang Y，Liu X，Shi H，et al. NLRP3 inflammasome，an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases [J]. Clin Transl Med，2020，10（1）：91-106.
[14] Groslambert M，Py BF. Spotlight on the NLRP3 inflammasome pathway [J]. J Inflamm Res，2018，11：359-374.
[15] Chen F，Chen ZQ，Zhong GL，et al. Nicorandil inhibits TLR4/MyD88/NF-kappaB/NLRP3 signaling pathway to reduce pyroptosis in rats with myocardial infarction [J]. Exp Biol Med（Maywood），2021，246（17）：1938-1947.
[16] Li L，Jiang M，Qi L，et al. Pyroptosis，a new bridge to tumor immunity [J]. Cancer Sci，2021，112（10）：3979-3994.
[17] He B，Nie Q，Wang F，et al. Role of pyroptosis in atherosclerosis and its therapeutic implications [J]. J Cell Physiol，2021，236（10）：7159-7175.
[18] van Hout GP，Bosch L，Ellenbroek GH，et al. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction [J]. Eur Heart J，2017，38（11）：828-836.
[19] Abplanalp WT，Cremer S，John D，et al. Clonal hematop- oiesis-driver DNMT3A mutations alter immune cells in heart failure [J]. Circ Res，2021，128（2）：216-228.
[20] Xu YJ，Zheng L，Hu YW，et al. Pyroptosis and its relationship to atherosclerosis [J]. Clin Chim Acta，2018，476：28-37.
[21] Zeng X，Liu D，Huo X，et al. Pyroptosis in NLRP3 inflammasome-related atherosclerosis [J]. Cell Stress，2022，6（10）：79-88.
[22] Qian Z，Zhao Y，Wan C，et al. Pyroptosis in the initiation and progression of atherosclerosis [J]. Front Pharmacol，2021， 12：652963.
[23] Yang Z，Shi J，Chen L，et al. Role of pyroptosis and ferroptosis in the progression of atherosclerotic plaques [J]. Front Cell Dev Biol，2022，10：811196.
[24] Bennett MR，Sinha S，Owens GK. Vascular smooth muscle cells in atherosclerosis [J]. Circ Res，2016，118（4）：692-702.
[25] Uddin M，Nguyen N，Yu B，et al. Clonal hematopoiesis of indeterminate potential，DNA methylation，and risk for coronary artery disease [J]. Nat Commun，2022，13（1）：5350.
[26] Bick AG，Pirruccello JP，Griffin GK，et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis [J]. Circulation，2020，141（2）：124- 131.
[27] Dempsey C，Rubio AA，Bryson KJ，et al. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-beta and cognitive function in APP/PS1 mice [J]. Brain Behav Immun，2017，61：306-316.
[28] Zhang L，Jiang YH，Fan C，et al. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis [J]. Biomed Pharmacother，2021，143：112133.
[29] Coll RC，Robertson AA，Chae JJ，et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases [J]. Nat Med，2015，21（3）：248-255.
[30] Zhang Y，Lv X，Hu Z，et al. Protection of Mcc950 against high-glucose-induced human retinal endothelial cell dysfunction [J]. Cell Death Dis，2017，8（7）：e2941.
[31] Estruch R，Ros E，Salas-Salvado J，et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts [J]. N Engl J Med，2018，378（25）：e34.
[32] Ma Q，Fan Q，Han X，et al. Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy [J]. J Control Release，2021，329：445-453.
[33] Zeng W，Wu D，Sun Y，et al. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages [J]. Sci Rep，2021，11（1）：19305.
[34] Byrne NJ，Matsumura N，Maayah ZH，et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 （nucleotide-binding domain-like receptor protein 3） inflammasome activation in heart failure [J]. Circ Heart Fail，2020，13（1）：e6277.